Tag Archives: chemotherapy

Phase II Trial of Phenoxodial Complete

INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released

Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial.  See the … Continue reading 

Posted in News | Also tagged , | Leave a comment

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian … Continue reading 

Posted in News | Also tagged , | Leave a comment

Chemosensitivity Assays for Ovarian Cancer

Point: Chemosensitivity Assays Have a Role in the Management of Recurrent Ovarian Cancer In this era of personalized medicine, patients with recurrent ovarian cancer deserve better than the 25% response … Continue reading 

Posted in News | Also tagged , | Leave a comment

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

Background: Because it is insufficiently clear whether BRCA-associated epithelial ovarian cancer (EOC) is more chemosensitive than sporadic EOC, we examined response to chemotherapy, progression-free survival (PFS) and overall survival (OS) … Continue reading 

Posted in News | Also tagged , | Leave a comment

Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer

This randomized, open label, phase III clinical trial (1988–1992) compared the efficacy and safety of a dose-dense regimen of single-agent cisplatin with a standard 3-weekly schedule in first-line chemotherapy for … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Study examines end-of-life care for cancer patients

Many in their final days receive costly, aggressive treatments they may not want, according to researchers at the Dartmouth Atlas of Health Care. In California, Los Angeles County had the … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study

Paclitaxel is one of the most common antitumour agents paclitaxel for the treatment of primary and relapsed ovarian cancer. Based on a German multicentre observational study, this article reflects the … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel

Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy. Methods Women aged 75 years or younger with newly … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Early versus delayed treatment of relapsed ovarian cancer

Background  Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the … Continue reading 

Posted in News | Also tagged , , | Leave a comment

New White Paper Issued on Ovarian Cancer

The Society of Gynecologic Oncologists (SGO) has issued a comprehensive white paper — as part the organization’s professional Gynecologic Cancer Collaborative education program — that provides an overview of and … Continue reading 

Posted in News | Also tagged , , , , , , , , | Leave a comment

Avastin helps in ovarian cancer but effects fade

Roche’s blockbuster drug Avastin helps women with ovarian cancer live longer without their disease getting worse, but its effect peaks at 12 months and then diminishes, researchers said on Monday. … Continue reading 

Posted in News | Also tagged , , , | Leave a comment